Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136169 · ClinicalTrials.gov registry record · NA
Reminder-cue Scanning Training for Homonymous Visual Field Loss
A NA study of Homonymous Hemianopia and Homonymous Quadrantanopia, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06136169: Recruiting NA study of Homonymous Hemianopia and Homonymous Quadrantanopia, sponsored by Massachusetts Eye and Ear Infirmary.
NCT06136169 is a NA study of Homonymous Hemianopia and Homonymous Quadrantanopia that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 30 participants, below the 46-participant average among 3 other Homonymous Hemianopia trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136169, a NA study of Homonymous Hemianopia and Homonymous Quadrantanopia, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate a new approach to training people with visual field loss to scan when driving
Primary Outcome
Percentage of intersections at which an early large head scan was made to the side of the field loss
Conditions Studied
Interventions
- BEHAVIORAL Reminder-cue scanning training
Study Locations (1)
Massachusetts
- Schepens Eye Research Institute of Mass Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06136169 shows while recruiting
NCT06136169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 46-participant average among 3 other Homonymous Hemianopia trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Homonymous Hemianopia appearing as the primary indexed condition, and to 1 intervention - of which Reminder-cue scanning training is the first listed.
NCT06136169 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06136169 about?
NCT06136169 is a clinical study titled "Reminder-cue Scanning Training for Homonymous Visual Field Loss". This study will evaluate a new approach to training people with visual field loss to scan when driving
What is the current status of trial NCT06136169?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-05-14. Estimated completion is 2026-05.
What conditions does trial NCT06136169 study?
This clinical trial studies the following conditions: Homonymous Hemianopia, Homonymous Quadrantanopia.
What interventions are being tested in trial NCT06136169?
The interventions under investigation include: Reminder-cue scanning training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06136169?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136169 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homonymous Hemianopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI